Showing results (241-250 of 300) with videos related to

Sort By:
Pageof 30
Leukemia|April 7, 2006
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplainedD P Steensma, R F McClure, J E Karp, et al.
Cancer Genetics and Cytogenetics|June 1, 1997
Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemiaA Tefferi, B J Bartholmai, T E Witzig, et al.
Leukemia|January 10, 2014
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsA Tefferi, T L Lasho, C M Finke, et al.
Bone Marrow Transplantation|December 2, 2000
Effect of complete response on outcome following autologous stem cell transplantation for myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Leukemia|October 29, 2011
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patientsM M Patnaik, C A Hanson, J M Hodnefield, et al.
Leukemia|July 28, 2006
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, T S Lasho, et al.
Bone Marrow Transplantation|May 11, 2004
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapyS Kumar, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|August 3, 2004
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myelomaS Kumar, M Q Lacy, A Dispenzieri, et al.
Leukemia|October 14, 2014
Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)T P Loughran, L Zickl, T L Olson, et al.
Pageof 30